Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference

WATERTOWN, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
April 30, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights

WATERTOWN, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
April 28, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors

WATERTOWN, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
April 07, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
March 12, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results

- Topline results from head-to-head COMPARE trial of SEL-212 in chronic refractory gout expected in Q3 2020 - - Received guidance from the FDA on SEL-212 Phase 3 clinical trial design; study to...
March 05, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

WATERTOWN, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
February 18, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

WATERTOWN, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
December 19, 2019 08:25 ET | Source: Selecta Biosciences, Inc.

AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...
December 19, 2019 08:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) --...
December 19, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces $70 Million Private Placement

WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...